Astrazeneca

FromAstraZeneca ([email protected])
Subject (106)Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial
Preheader (106)Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial
Typography
Arial
Colors
Text Analysis
Body Words218
Subject Words14
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px792 px
X-Spam Score-5.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial
Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial